Open Access

Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma

  • Authors:
    • Wen‑Yan Cai
    • Ying Zhuang
    • Fei Yan
    • Ting Li
    • Wen‑Ting Song
    • Jin‑Hu Sun
  • View Affiliations

  • Published online on: June 22, 2018     https://doi.org/10.3892/mmr.2018.9204
  • Pages: 1939-1946
  • Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Simvastatin, an inhibitor of 3‑hydroxy‑3-methylglutaryl‑coenzyme A reductase, is been used in the clinic due to its pleiotropic effects, such as breast cancer, prostate cancer, pancreatic cancer. Simvastatin has recently been demonstrated to serve a potential role in the prophylaxis and therapeutics of a number of human cancers. The majority of reports concerning simvastatin treatment in the majority of human cancers have demonstrated that survivin is significantly decreased as a result and has been implicated in tumorigenesis. However, only a limited number of studies have investigated the use of simvastatin for the treatment of salivary gland adenoid cystic carcinoma (SACC). Therefore, this agent is a candidate for further investigation. The aim of the present study was to investigate the effects of simvastatin on the proliferation, invasion and apoptosis of the human salivary adenoid cystic carcinoma cell line, SACC‑83, as well as survivin expression in the cells. The Cell Counting kit‑8 assay results revealed that simvastatin inhibited the proliferation of SACC‑83 cells in a dose‑dependent (10 to 50 µM) and time‑dependent (24 to 48 h) manner when compared with the untreated cells. Flow cytometry analysis indicated that simvastatin increased the percentage of cells in early and late apoptosis. Invasion assays revealed that simvastatin treatment inhibited the invasiveness of SACC‑83 cells in a dose‑dependent manner. In addition, simvastatin downregulated survivin expression in SACC‑83 cells. In conclusion, simvastatin significantly inhibited the proliferation and invasion of SACC‑83 cells, induced apoptosis, and reduced the expression of survivin, which suggests that simvastatin may be a novel target for SACC therapy.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 18 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cai WY, Zhuang Y, Yan F, Li T, Song WT and Sun JH: Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma. Mol Med Rep 18: 1939-1946, 2018
APA
Cai, W., Zhuang, Y., Yan, F., Li, T., Song, W., & Sun, J. (2018). Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma. Molecular Medicine Reports, 18, 1939-1946. https://doi.org/10.3892/mmr.2018.9204
MLA
Cai, W., Zhuang, Y., Yan, F., Li, T., Song, W., Sun, J."Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma". Molecular Medicine Reports 18.2 (2018): 1939-1946.
Chicago
Cai, W., Zhuang, Y., Yan, F., Li, T., Song, W., Sun, J."Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma". Molecular Medicine Reports 18, no. 2 (2018): 1939-1946. https://doi.org/10.3892/mmr.2018.9204